In the past week, NUVB stock has gone down by -2.93%, with a monthly gain of 10.37% and a quarterly surge of 2.76%. The volatility ratio for the week is 5.72%, and the volatility levels for the last 30 days are 7.01% for Nuvation Bio Inc The simple moving average for the last 20 days is -0.90% for NUVB stock, with a simple moving average of 16.79% for the last 200 days.
Is It Worth Investing in Nuvation Bio Inc (NYSE: NUVB) Right Now?
The stock has a 36-month beta value of 1.39. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for NUVB is 145.81M, and at present, short sellers hold a 12.32% of that float. On September 18, 2024, the average trading volume of NUVB was 1.67M shares.
NUVB) stock’s latest price update
Nuvation Bio Inc (NYSE: NUVB)’s stock price has plunge by -2.93relation to previous closing price of 3.07. Nevertheless, the company has seen a -2.93% plunge in its stock price over the last five trading sessions. businesswire.com reported 2024-09-14 that NEW YORK–(BUSINESS WIRE)–Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced positive pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies evaluating taletrectinib, an investigational next-generation ROS1 TKI. The findings will be highlighted in a poster presentation on September 14, 2024, at the European Society of Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain.
Analysts’ Opinion of NUVB
Many brokerage firms have already submitted their reports for NUVB stocks, with Jefferies repeating the rating for NUVB by listing it as a “Buy.” The predicted price for NUVB in the upcoming period, according to Jefferies is $10 based on the research report published on March 27, 2024 of the current year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see NUVB reach a price target of $5. The rating they have provided for NUVB stocks is “Buy” according to the report published on March 26th, 2024.
Jefferies gave a rating of “Hold” to NUVB, setting the target price at $2 in the report published on January 06th of the previous year.
NUVB Trading at -4.72% from the 50-Day Moving Average
After a stumble in the market that brought NUVB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.36% of loss for the given period.
Volatility was left at 7.01%, however, over the last 30 days, the volatility rate increased by 5.72%, as shares surge +4.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.54% lower at present.
During the last 5 trading sessions, NUVB fell by -2.28%, which changed the moving average for the period of 200-days by +141.94% in comparison to the 20-day moving average, which settled at $3.01. In addition, Nuvation Bio Inc saw 97.35% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NUVB starting from Cui Xiangmin, who purchase 277,895 shares at the price of $2.97 back on Jun 25 ’24. After this action, Cui Xiangmin now owns 2,453,131 shares of Nuvation Bio Inc, valued at $825,348 using the latest closing price.
Cui Xiangmin, the Director of Nuvation Bio Inc, purchase 336,874 shares at $2.98 during a trade that took place back on Jun 24 ’24, which means that Cui Xiangmin is holding 2,175,236 shares at $1,003,885 based on the most recent closing price.
Stock Fundamentals for NUVB
Current profitability levels for the company are sitting at:
- -66.32 for the present operating margin
- -0.04 for the gross margin
The net margin for Nuvation Bio Inc stands at -300.6. The total capital return value is set at -0.21. Equity return is now at value -115.83, with -82.63 for asset returns.
Based on Nuvation Bio Inc (NUVB), the company’s capital structure generated 0.53 points at debt to capital in total, while cash flow to debt ratio is standing at -0.29. The debt to equity ratio resting at 1.12. The interest coverage ratio of the stock is -22.87.
Currently, EBITDA for the company is -99.6 million with net debt to EBITDA at -2.27. When we switch over and look at the enterprise to sales, we see a ratio of 579.13. The receivables turnover for the company is 0.42for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.49.
Conclusion
To sum up, Nuvation Bio Inc (NUVB) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
